BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19463265)

  • 1. Receptor reserve reflects differential intrinsic efficacy associated with opioid diastereomers.
    Carliss RD; Keefer JF; Perschke S; Welch S; Rich TC; Weissman AD
    Pharmacol Biochem Behav; 2009 May; 92(3):495-502. PubMed ID: 19463265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on kinetics of [3H]beta-funaltrexamine binding to mu opioid receptor.
    Liu-Chen LY; Li SX; Tallarida RJ
    Mol Pharmacol; 1990 Feb; 37(2):243-50. PubMed ID: 2154672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mu-opioid receptor ligands lack receptor subtype selectivity in the aequorin luminescence-based calcium assay.
    Fichna J; Staniszewska R; Poels J; Vanden Broeck J; Janecka A
    Chem Biol Drug Des; 2007 Sep; 70(3):247-53. PubMed ID: 17718719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.
    Spetea M; Schüllner F; Moisa RC; Berzetei-Gurske IP; Schraml B; Dörfler C; Aceto MD; Harris LS; Coop A; Schmidhammer H
    J Med Chem; 2004 Jun; 47(12):3242-7. PubMed ID: 15163203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.
    Valenzano KJ; Miller W; Chen Z; Shan S; Crumley G; Victory SF; Davies E; Huang JC; Allie N; Nolan SJ; Rotshteyn Y; Kyle DJ; Broglé K
    J Pharmacol Exp Ther; 2004 Aug; 310(2):783-92. PubMed ID: 15054115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats.
    Peckham EM; Traynor JR
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1195-201. PubMed ID: 16291875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid peptide receptor studies. 14. Stereochemistry determines agonist efficacy and intrinsic efficacy in the [(35)S]GTP-gamma-S functional binding assay.
    Xu H; Hashimoto A; Rice KC; Jacobson AE; Thomas JB; Carroll FI; Lai J; Rothman RB
    Synapse; 2001 Jan; 39(1):64-9. PubMed ID: 11071711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.
    Greiner E; Spetea M; Krassnig R; Schüllner F; Aceto M; Harris LS; Traynor JR; Woods JH; Coop A; Schmidhammer H
    J Med Chem; 2003 Apr; 46(9):1758-63. PubMed ID: 12699394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. beta-Funaltrexamine, a gauge for the recognition site of wildtype and mutant H297Q mu-opioid receptors.
    Spivak CE; Beglan CL; Zöllner C; Surratt CK
    Synapse; 2003 Jul; 49(1):55-60. PubMed ID: 12710015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites.
    Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF
    Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of opioid mu-receptor by sinomenine in cell and mice.
    Wang MH; Chang CK; Cheng JH; Wu HT; Li YX; Cheng JT
    Neurosci Lett; 2008 Oct; 443(3):209-12. PubMed ID: 18692550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor.
    Cox EH; Kerbusch T; Van der Graaf PH; Danhof M
    J Pharmacol Exp Ther; 1998 Mar; 284(3):1095-103. PubMed ID: 9495871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
    Le Bourdonnec B; Goodman AJ; Graczyk TM; Belanger S; Seida PR; DeHaven RN; Dolle RE
    J Med Chem; 2006 Dec; 49(25):7290-306. PubMed ID: 17149859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice.
    Yancey-Wrona JE; Raymond TJ; Mercer HK; Sadée W; Bilsky EJ
    Life Sci; 2009 Sep; 85(11-12):413-20. PubMed ID: 19583969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan.
    Srivastava SK; Shefali S; Miller CN; Aceto MD; Traynor JR; Lewis JW; Husbands SM
    J Med Chem; 2004 Dec; 47(26):6645-8. PubMed ID: 15588100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of agmatine on DAMGO-induced mu-opioid receptor down-regulation and internalization via activation of IRAS, a candidate for imidazoline I(1) receptor.
    Gao Y; Li F; Wu N; Su RB; Liu Y; Lu XQ; Liu Y; Li J
    Eur J Pharmacol; 2008 Dec; 599(1-3):18-23. PubMed ID: 18845140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separation of binding affinity and intrinsic activity of the potent mu-opioid 14-methoxymetopon.
    Mahurter L; Garceau C; Marino J; Schmidhammer H; Tóth G; Pasternak GW
    J Pharmacol Exp Ther; 2006 Oct; 319(1):247-53. PubMed ID: 16801454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of mu-opioid receptor antagonists.
    Le Bourdonnec B; Goodman AJ; Michaut M; Ye HF; Graczyk TM; Belanger S; Herbertz T; Yap GP; DeHaven RN; Dolle RE
    J Med Chem; 2006 Dec; 49(25):7278-89. PubMed ID: 17149858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of agmatine on calcium signal in morphine-dependent CHO cells by activation of IRAS, a candidate for imidazoline I1 receptor.
    Wu N; Su RB; Liu Y; Lu XQ; Zheng JQ; Cong B; Li J
    Eur J Pharmacol; 2006 Oct; 548(1-3):21-8. PubMed ID: 16962578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.